Global /South Korea /Healthcare /Drug Manufacturers - General /005500

Samjin Pharmaceuticals Co., Ltd.

005500

• KRX: 005500 • Delayed

18,720KRW -1.4%

12.40 USD

As of 19 June 2026, Samjin Pharmaceuticals Co., Ltd. has a market cap of $152.61M USD, ranking #22784 globally and #979 in South Korea. It ranks #2044 in the Healthcare sector, and #735 in the Drug Manufacturers - General industry.

Global Rank

22784

Country Rank

979

Sector Rank

2044

Industry Rank

735

Key Stats

Market Cap

$152.61MUSD

232.78B KRW

Revenue (TTM)

$179.66MUSD

274.03B KRW

EBITDA (TTM)

$21.86MUSD

33.0B KRW

Net Income (TTM)

$14.35MUSD

21.89B KRW

EBITDA Margin

12%

Profit Margin

PE Ratio

11.0

Forward PE

11.4

PS Ratio

0.8

PB Ratio

0.8

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Yong-Joo Choi open_in_new

Employees

586

Founded

1968

Website

samjinpharm.co.kr open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.4%	1.9%	2.4%	-1.9%	-5%	-3.8%	7%	-17%	-29%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	005500 삼진제약(주) ISIN: KR7005500004 Shares Out.: Shares Outstanding: 12.658M¹ Shares Float: 6.358M² TV: TradingView: KRX: 005500 SA: Stock Analysis: KRX: 005500 YF: Yahoo Finance: 005500.KS GF: Google Finance: KRX: 005500 BA: Barron's: 005500 MS: Morningstar: XKRX: 005500	18,720 KRW	TV: TradingView: KRX: 005500 SA: Stock Analysis: KRX: 005500 YF: Yahoo Finance: 005500.KS GF: Google Finance: KRX: 005500 BA: Barron's: 005500 MS: Morningstar: XKRX: 005500

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Samjin Pharmaceuticals Co., Ltd.

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer’s and Parkinson’s disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.12B 13.91T KRW 6K%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.75B 10.3T KRW 4K%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.23B 7.97T KRW 3K%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$4.95B 7.55T KRW 3K%	-	South Korea
Yuhan Corp. KRX: 000100	$4.54B 6.92T KRW 3K%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.43B 6.76T KRW 3K%	-	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 499K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 359K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 236K%	97.4	United States
Roche Holding AG SIX: RO	$321.45B 256.25B CHF 211K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$287.52B 215.59B GBP 188K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.59B 218.9B CHF 180K%	20.5	Switzerland

chevron_leftBack